NUKLEONIKA 2006, 51(2):119-123
Amir R. Jalilian, Yousef Yari-Kamrani, Mahdi Sadeghi
Cyclotron and Nuclear Medicine Department, Nuclear Research Center for Agriculture
and Medicine (NRCAM), Atomic Energy Organization of Iran (AEOI), Moazzen Blvd., Rajaee shahr, Karaj, Iran,
P. O. Box 31485-498
Due to the anticancer properties of bleomycin (BLM) complexes, production of [103Pd]bleomycin
([103Pd]BLM) was targeted. Palladium-103 (T1/2 = 16.96 d) was produced
via the 103Rh(p,n)103Pd nuclear reaction using a natural rhodium target.
Proton energy was 18 MeV with 200 mA irradiation for 15 h
(final activity 25.9 GBq of 103Pd2+, RCP > 95%, radionuclidic purity > 99%).
103Pd was separated from the irradiated target by anion exchange using a Dowex 1´8
(Cl-)/100-200 mesh resin in the form of Pd(NH3)2Cl2 in order to react
with bleomycin to yield [103Pd]BLM. Chemical purity of the final product was in
accordance to the accepted limits. [103Pd]BLM was prepared with a radiochemical yield
of more than 98% at 80°C in 30 min. The labeling reaction was optimized for time, temperature
and ligand concentration. Radiochemical purity of more than 99% was obtained using RTLC with specific
activity of about 370 MBq/mmol. The stability of the tracer was checked in the final product
and presence of human serum at up to 3 h. The complex was stable in human serum at 37°C up to
2 h of incubation. Biodistribution studies using a SPECT system performed in normal rats in
the first 2-3 h.